Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03841357 · ClinicalTrials.gov registry record · Phase 3
Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA)
A Phase 3 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 3
- Development phase
- 121
- Enrollment target
NCT03841357: Completed Phase 3 study, sponsored by Duke University.
NCT03841357 is a Phase 3 study that has completed, run by Duke University. The registered enrollment target is 121 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (84% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03841357, a Phase 3 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 121 participants
- Enrollment target
Study Summary
This is a research study to test whether a once-weekly injection of abatacept will prevent the progression of Juvenile Idiopathic Arthritis (JIA) to a more severe form. To evaluate the effectiveness of a 24-week course of treatment with abatacept plus usual care versus usual care to prevent polyarthritis (≥5 joints), uveitis, or treatment with other systemic medication within 18 months of randomization in children with recent-onset limited JIA.
Primary Outcome
Any of the following from randomization to day 410: polyarthritis \[\>=5 cumulative active joint count\], uveitis, initiation of systemic glucocorticoids (IV or PO), DMARDs or biologics.
Interventions
- OTHER Usual Care
- DRUG Abatacept Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2019-10-29 |
| Est. Completion | 2025-01-22 |
| Phase | Phase 3 |
What the finished NCT03841357 record still lists
NCT03841357 is an interventional study that assigns participants to a tested intervention. The registered 121 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (84% lower).
The record links to 0 conditions, and to 2 interventions - of which Usual Care is the first listed.
NCT03841357 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03841357 about?
NCT03841357 is a clinical study titled "Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA)". This is a research study to test whether a once-weekly injection of abatacept will prevent the progression of Juvenile Idiopathic Arthritis (JIA) to a more severe form. To evaluate the effectiveness of a 24-week course of treatment with abatacept plus usual care versus usual care to prevent polyarth...
What is the current status of trial NCT03841357?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 121 participants. The study started on 2019-10-29. Estimated completion is 2025-01-22.
What interventions are being tested in trial NCT03841357?
The interventions under investigation include: Usual Care (OTHER), Abatacept Injection (DRUG).
Who is sponsoring clinical trial NCT03841357?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03841357's enrollment target sits among peer trials
121 1619th of 2000 higher than 382 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03476681 · 121 participants · Phase 1
Study of NEO-201 in Solid Tumors Expansion Cohorts
- NCT04655118 · 121 participants · Phase 2
Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
- NCT04676802 · 121 participants · Phase 2
Pain Relief After Trapeziectomy: Ibuprofen & Acetaminophen Versus Oxycodone
- NCT05169515 · 121 participants · Phase 1
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI